## 4 Conclusions
\begin{table}
\begin{tabular}{c l c} \hline
**Biactive Effects** & **Mechanisms** & **References** \\ \hline \multirow{7}{*}{O Oxidative stress} & Enhance cognitive function & [67] \\  & Reduce nitric oxide and MDA levels & [67] \\ \cline{2-3}  & Inhib cellular lipid peroxidation and decrease H\({}_{2}\)O\({}_{2}\)-induced COX-2 expression & [67] \\ \cline{2-3}  & Enhance defense system of endogenous antioxidant & [73,74] \\  & Decrease 4-HNE expression & [73,74] \\ \cline{2-3}  & Down-regulate N\(\cdot\)kB & [69] \\ \cline{2-3}  & Increase CAT, HO-1, SOD activity and expression & [70] \\  & Reduce factor Nrf2 transcription & [70] \\ \cline{2-3}  & Inhib liver fibrosis progression and activation & [85,86] \\ \cline{2-3}  & Prevent +SMA expression and TGF-81 & [84] \\ \hline \multirow{3}{*}{Antidepressant} & Restor hippocampal BDNF and pERK/12 protein expression & [94] \\ \cline{2-3}  & InhibImmunoin oxidase and monomarine transporters & [138] \\ \cline{2-3}  & Up-regulate PC and TH & [95] \\ \cline{2-3}  & Decrease serum levels of blood urea nitrogen and creatinine & [99] \\ \cline{2-3}  & Decrease myeloproscales and MDA levels & [99] \\ \cline{2-3}  & Repres NT-a and N\(\cdot\)kB-expression, demonstrating inhibition of inflammation & [100] \\ \cline{2-3}  & Reduce p53, phosphorylated p53, and active caspase-3-expression & [100] \\ \hline \multirow{3}{*}{Anti-aging} & Reduce protein carbonyls in the hippocampus & [106] \\ \cline{2-3}  & Attanate disruption of LDH, intercellular ROS, and mitochondrial membrane potential & [113] \\ \cline{2-3}  & Improves oxidative stress parameters and mitochondrial respiratory chain activity & [108] \\ \cline{2-3}  & Inhib phosphorylated p53 MAPK & [110,111] \\ \cline{2-3}  & Exent antioxidant effects against 6-hy droydopamine facilitate neurotoxicity & [139,140] \\ \cline{2-3}  & Restor activity of complex 1 of mitochondrial respiratory chain & [68,109] \\ \cline{2-3}  & Prevent amyloid peptide aggregation & [68,109] \\ \cline{2-3}  & Decrease eosinophils number & [118] \\ \cline{2-3}  & Inhib IgE, protein levels and mRNA expressions of IL-6, IL-19, and TNF-a and reduce histamine levels & [120,121] \\ \cline{2-3}  & Suppress IL-4 and INF production & [119] \\ \cline{2-3}  & Inhib skin lesions development and ears thickness & [120] \\ \hline \end{tabular}
\end{table} 
Table 1: _Cont._ \begin{table}
\begin{tabular}{c l c} \hline \hline
**Biocative Effects** & **Mechanisms** & **References** \\ \hline Anti-inflammatory & InhibT2 & cytokines, ameliorate AIR \\  & Reduce total IgE and Ova-specific IgE concentrations & [129] \\  & Reduce Yinz, CCGs, CC11, AMCase, and E-selectin mRNA expression \\  & InhibT5-induced NO production \\  & Repress LPS-induced pro-inflammatory cytokines expression including INF-\(\beta\), monocyte chemo attractant protein-1, iNOS, IL-\(\beta\), IL-\(\epsilon\), IL-10, \\  & and activation of NF-\(\epsilon\)B \\  & Decrease serum transaminase (ALT and AST) and LDH levels & [130] \\  & InhibT-\(\epsilon\)B \\  & Reduce oxidative stress levels and down-regulate NF-\(\epsilon\)B & [69] \\ \hline \hline \end{tabular}
\end{table} 
Table 1: _Cont._  
**Author Contributions:** All authors contributed to the manuscript. Conceptualization: M.I., M.N. and J.S.-R., Validation investigation, resources, data curation, writing: all authors; review and editing: B.S., J.S. [PERSON]R., W.C.C. and N.M. All the authors read and approved the final manuscript. **Funding:** None. **Acknowledgments:** [PERSON] thank to Portuguese Foundation for Science and Technology (FCT-Portugal) for the Strategic project ref. UID/BIM/04293/2013 and \"NORTE2020-Programa Operacional Regional do Norte\" (NORTE-01-0145-FEDER-000012). Also, this work was supported by CONICYT PIA/APOYO CCTE AFB170007. **Conflicts of Interest:** The authors declare no conflict of interest.